The High Cost of Cancer Drugs and What We Can Do About It

被引：185

作者：

Siddiqui, Mustaqeem ^{[2
]}

Rajkumar, S. Vincent ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Hosp Internal Med, Rochester, MN 55905 USA

来源：

MAYO CLINIC PROCEEDINGS | 2012年 / 87卷 / 10期

关键词：

MAYO STRATIFICATION; CHEMOTHERAPY DRUGS; MULTIPLE-MYELOMA; MANAGEMENT; THERAPY; HEALTH; ATORVASTATIN; INITIATION; RATES;

D O I：

10.1016/j.mayocp.2012.07.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：935 / 943

页数：9

共 42 条

[1] Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines [J].

Ansell, Stephen M. ;

Kyle, Robert A. ;

Reeder, Craig B. ;

Fonseca, Rafael ;

Mikhael, Joseph R. ;

Morice, William G. ;

Bergsagel, P. Leif ;

Buadi, Francis K. ;

Colgan, Joseph P. ;

Dingli, David ;

Dispenzieri, Angela ;

Greipp, Philip R. ;

Habermann, Thomas M. ;

Hayman, Suzanne R. ;

Inwards, David J. ;

Johnston, Patrick B. ;

Kumar, Shaji K. ;

Lacy, Martha Q. ;

Lust, John A. ;

Markovic, Svetomir N. ;

Micallef, Ivana N. M. ;

Nowakowski, Grzegorz S. ;

Porrata, Luis F. ;

Roy, Vivek ;

Russell, Stephen J. ;

Short, Kristen E. Detweiler ;

Stewart, A. Keith ;

Thompson, Carrie A. ;

Witzig, Thomas E. ;

Zeldenrust, Steven R. ;

Dalton, Robert J. ;

Rajkumar, S. Vincent ;

Gertz, Morie A. .

MAYO CLINIC PROCEEDINGS, 2010, 85 (09) :824-833

[2] Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs [J].

Bach, Peter B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06) :626-633

[3] Is Initiation of Atorvastatin for Employees a Good Buy for Employers? [J].

Culler, Steven D. ;

Weintraub, William S. .

MAYO CLINIC PROCEEDINGS, 2009, 84 (12) :1059-1061

[4]

de Souza JA, 2011, ASCO M, V29, P6002

[5] Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs [J].

DiMasi, J. A. ;

Feldman, L. ;

Seckler, A. ;

Wilson, A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :272-277

[6] Economics of new oncology drug development [J].

DiMasi, Joseph A. ;

Grabowski, Henry G. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (02) :209-216

[7] Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006 [J].

Dinan, Michaela A. ;

Curtis, Lesley H. ;

Hammill, Bradley G. ;

Patz, Edward F., Jr. ;

Abernethy, Amy P. ;

Shea, Alisa M. ;

Schulman, Kevin A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (16) :1625-1631

[8]

Erickson P, 1995, Healthy People 2000 Stat Notes, P1

[9] Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group [J].

Fraser, Judith ;

Steele, Nicola ;

Al Zaman, Aysha ;

Yule, Alison .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) :215-220

[10] The Shortage of Essential Chemotherapy Drugs in the United States [J].

Gatesman, Mandy L. ;

Smith, Thomas J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1653-1655

← 1 2 3 4 5 →